The tumour microenvironment and implications for cancer immunotherapy (Q36521830)

From Wikidata

Jump to navigation Jump to search

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

scientific article published on July 2006

Language	Label	Description	Also known as
English	The tumour microenvironment and implications for cancer immunotherapy	scientific article published on July 2006

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

1 reference

Europe PubMed Central

The tumour microenvironment and implications for cancer immunotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

1 reference

based on heuristic

inferred from title

Howard L. Kaufman

3

object named as

Howard L Kaufman

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

author name string

Christian A Petrulio

1

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

Seunghee Kim-Schulze

2

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

language of work or name

0 references

publication date

1 July 2006

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

Expert Opinion on Biological Therapy

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

671-684

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

Know thy neighbor: stromal cells can contribute oncogenic signals

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Tumor-infiltrating T lymphocytes: friends or foes?

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

p53 mutations in human cancers

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

The role of Fas/FasL in immunosuppression induced by human tumors

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

22. Immune responses to malignancies

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2‐microglobulin inactivation in MSI‐positive tumors and LMP7/TAP2 downregulation in MSI‐negative tumors

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

MHC class I antigens, immune surveillance, and tumor immune escape.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Relationship between co-stimulatory molecule B7-H3 expression and gastric carcinoma histology and prognosis

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Regulation and role of TGF beta production in breast cancer

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

IL-10 expression by CT26 colon carcinoma cells inhibits their malignant phenotype and induces a T cell-mediated tumor rejection in the context of a systemic Th2 response

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Microscope-based multiparameter laser scanning cytometer yielding data comparable to flow cytometry data

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Analysis of p53, p21WAF1, and TGF-beta1 in human ductal adenocarcinoma of the pancreas: TGF-beta1 protein expression predicts longer survival

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Transforming growth factor beta 1 as a prognostic factor in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Cytokine profiles in spontaneously regressing basal cell carcinomas

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

The interleukin (IL)-2 family cytokines: survival and proliferation signaling pathways in T lymphocytes

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE)

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

S100A7 and the progression of breast cancer

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Indoleamine 2,3 dioxygenase and regulation of T cell immunity

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Prevention of allogeneic fetal rejection by tryptophan catabolism

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

L-arginine consumption by macrophages modulates the expression of CD3 zeta chain in T lymphocytes

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Lymphocyte apoptosis induced by Fas ligand- expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Immunoglobulin genes expressed by B-lymphocytes infiltrating cervical carcinomas show evidence of antigen-driven selection.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Targeted cancer therapy using radiolabeled monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Maturation requirements for dendritic cells in T cell stimulation leading to tolerance versus immunity

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Cyclooxygenase-2 inhibition: a potential mechanism for increasing the efficacy of bacillus calmette-guerin immunotherapy for bladder cancer.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Inhibition of activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Combination B7-Fc fusion protein treatment and Treg cell depletion therapy

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Anti-angiogenic therapy as a cancer treatment paradigm

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Role of angiogenesis in tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Angiogenesis in health and disease

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Stromal fibroblasts in cancer initiation and progression

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Hypoxia and anemia: effects on tumor biology and treatment resistance

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Relevance of tumor microenvironment for progression, therapy and drug development

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Microenvironmental and cellular consequences of altered blood flow in tumours

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Alterations in proteolytic activity at low pH and its association with invasion: a theoretical model.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Manipulating the local tumor microenvironment with poxviruses expressing costimulatory molecules

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Regulatory T cells in ovarian cancer: biology and therapeutic potential

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases

1 reference

https://api.crossref.org/works/10.1517%2F14712598.6.7.671

21 January 2018

Identifiers

10.1517/14712598.6.7.671

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

14 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36521830&oldid=1636672824"